{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:00:38Z","timestamp":1790103638721,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study evaluates the clinical efficacy and safety of adding an oral probiotic preparation to tacrolimus ointment in children with atopic dermatitis and assesses its effects on serum total immunoglobulin E, interleukin-4, and leukotriene B4. This single-center retrospective cohort study included 92 children with atopic dermatitis treated between March 2023 and March 2025. Treatment exposure reflected routine clinical practice. To reduce confounding by indication, propensity scores were estimated from age, sex, disease duration, baseline SCORing Atopic Dermatitis (SCORAD), baseline total immunoglobulin E, physician-diagnosed food allergy, and passive smoking exposure. A 1:1 nearest-neighbor propensity score matching analysis without replacement was performed using a caliper of 0.2 standard deviations of the logit of the propensity score. Covariate balance was assessed using standardized mean differences (SMDs), with SMD &lt;0.10 indicating adequate balance. The primary outcomes were change in SCORAD and clinical response (\u226550% reduction in SCORAD) at week 12. In the original cohort, the combination group had a greater mean reduction in SCORAD than the tacrolimus group (29.2\u2005\u00b1\u200510.4 vs 23.7\u2005\u00b1\u200511.0; unadjusted between-group difference 5.5 points;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.004), and the response rate was higher (82.6% vs 60.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.018). In the simulated propensity score matching sensitivity analysis, 38 matched pairs were retained, and all post-matching SMDs were &lt;0.10. Combination therapy remained associated with clinical response in the matched cohort (odds ratio\u2005=\u20052.76, 95% confidence interval\u2005=\u20051.05\u20137.27;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.039). A multivariable model additionally adjusting for food allergy and passive smoking exposure produced a consistent estimate (adjusted odds ratio\u2005=\u20052.91, 95% confidence interval\u2005=\u20051.16\u20137.31;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.022). In this single-center retrospective cohort, adjunctive use of the specified probiotic formulation was associated with greater short-term improvement than tacrolimus-based care alone. The consistency of the association in the simulated propensity-matched sensitivity analysis supports robustness to measured baseline differences, but residual and unmeasured confounding cannot be excluded. The incremental 5.5-point between-group difference in SCORAD reduction was smaller than the commonly cited 8.7-point within-patient minimal clinically important difference and should therefore be interpreted cautiously. Prospective randomized studies with longer follow-up are required.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050451","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:02:07Z","timestamp":1789750927000},"page":"e50451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of probiotics combined with tacrolimus ointment in children with atopic dermatitis and its effects on serum IgE, IL-4, and LTB4"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2407-2677","authenticated-orcid":false,"given":"Jianbo","family":"Zhu","sequence":"first","affiliation":[{"name":"Dermatology Department, Danyang Maternal and Child Health Care Hospital, Danyang City, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Bu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Danyang Maternal and Child Health Care Hospital, Danyang City, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis.","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review.","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"e2025071812","DOI":"10.1542\/peds.2025-071812","article-title":"Atopic dermatitis: update on skin-directed management: clinical report.","volume":"155","author":"Schoch","year":"2025","journal-title":"Pediatrics"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis.","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"1202325","DOI":"10.3389\/fphar.2023.1202325","article-title":"A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children.","volume":"14","author":"Mohamed","year":"2023","journal-title":"Front Pharmacol"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12887-022-03390-3","article-title":"Gut microbiota and atopic dermatitis in children: a scoping review.","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Pediatr"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1038\/s41598-019-41149-6","article-title":"Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture.","volume":"9","author":"Reddel","year":"2019","journal-title":"Sci Rep"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"833666","DOI":"10.3389\/fnut.2021.833666","article-title":"Efficacy of probiotics in children and adolescents with atopic dermatitis: a randomized, double-blind, placebo-controlled study.","volume":"8","author":"de Andrade","year":"2022","journal-title":"Front Nutr"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.3390\/ijms23105409","article-title":"Probiotics function in preventing atopic dermatitis in children.","volume":"23","author":"Anania","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R11-20260922","first-page":"361","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2021 (English version).","volume":"49","author":"Saeki","year":"2022","journal-title":"J Dermatol"},{"key":"R12-20260922","first-page":"153","article-title":"Consensus-based guidelines for the treatment of atopic dermatitis.","volume":"36","author":"Ko","year":"2024","journal-title":"Ann Dermatol"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R15-20260922","first-page":"5","article-title":"Role of the gut microbiota in atopic dermatitis: a systematic review.","volume":"99","author":"Petersen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"1613315","DOI":"10.3389\/fmicb.2025.1613315","article-title":"Current insights and trends in atopic dermatitis and microbiota interactions: a systematic review and bibliometric analysis.","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Microbiol"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"e12283","DOI":"10.1002\/clt2.12283","article-title":"Efficacy of probiotics in pediatric atopic dermatitis: a systematic review and meta-analysis.","volume":"13","author":"Xue","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/nu13041169","article-title":"The effectiveness of probiotic Lactobacillus rhamnosus and Lactobacillus casei strains in children with atopic dermatitis and cow\u2019s milk protein allergy: a multicenter, randomized, double blind, placebo controlled study.","volume":"13","author":"Cukrowska","year":"2021","journal-title":"Nutrients"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1684\/ejd.2021.4019","article-title":"Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial.","volume":"31","author":"Michelotti","year":"2021","journal-title":"Eur J Dermatol"},{"key":"R20-20260922","first-page":"367","article-title":"Neutrophils in atopic dermatitis.","volume":"66","author":"Chiang","year":"2024","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:03:28Z","timestamp":1790100208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050451"}},"subtitle":["A single-center retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":19,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050451","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}